ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

15 Health Benefits of Chia Seeds, According to Science

Natural Remedies for the Prevention of Dry Eyes

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

Magnesium Deficiency Raises Your Risk of Many Chronic Ailments

Resveratrol supplementation improves arterial stiffness in type 2 diabetics

What Makes Spanish Marjoram Oil Special?

CoQ10's Potential Capabilities for Your Health

How Can Melatonin Benefit You?

Cloves: Boost Your Immune System the Sweet and Spicy Way

8 Chia Seed Recipes

 
Print Page
Email Article

New Study Aims to Prevent Heart Disease in Pediatric Lupus Patients

  [ 80 votes ]   [ Discuss This Article ]
www.ProHealth.com • September 8, 2003


DURHAM, NC -- Researchers from Duke University Medical Center will study the use of cholesterol-lowering drugs to prevent heart disease in pediatric patients with lupus erythematosus. Atherosclerosis, or hardening of the arteries caused by fat buildup, is a complication of increasing concern to physicians treating children with lupus.

Atherosclerosis puts young lupus patients at high risk for cardiac problems including heart attack or stroke.

According to recent research, the risk of heart attack in young, female lupus patients is as much as 50 times greater than in women of the same age who do not have lupus. Lupus affects approximately 15,000 children in the United States, 90 percent of whom are female.

The Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial will study the effect of statins, drugs used to lower cholesterol levels, in preventing buildup of fat in the arteries. The trial will include 280 pediatric lupus patients at 20 sites throughout the United States and Canada, and will be coordinated by the Duke Clinical Research Institute. Laura Schanberg, M.D., associate professor of pediatrics at Duke, and Christy Sandborg, M.D., associate professor of pediatrics at Stanford University School of Medicine, will lead the trial.

The APPLE trial is funded by a $10 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the National Institutes of Health (NIH).

The APPLE trial will be a randomized study in which half of the participants receive atorvastatin (trade name Lipitor), plaquenil (a treatment commonly used for lupus patients), folate and dietary counseling, all in addition to their standard lupus treatments. The other half of the group will receive a placebo instead of atorvastatin, but will be given plaquenil, folate and dietary counseling along with standard lupus medications.

Neither the physicians nor the patients will know which patients are given atorvastatin and which receive placebo. Physicians will follow participants for three years using ultrasound to monitor progression of atherosclerosis.

The researchers hope this trial will lead to a new method of preventing cardiac disease in lupus patients. "We hope we will find that the patients treated with atorvastatin will exhibit a much lower rate of atherosclerosis, and therefore a lower risk for heart attack and stroke." said Schanberg.

"This trial is the first large-scale pediatric rheumatology trial of its kind," she said. "It is especially exciting because it is a collaboration among government, medical institutions, the pharmaceutical industry and the Childhood Arthritis and Rheumatology Research Alliance (CARRA)."

The trial will begin enrolling patients in fall of 2003.

Neither Schanberg nor Sandborg has any financial affiliation with Pfizer, Inc., the manufacturer of atorvastatin.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS
Bone Broth Benefits for Digestion, Arthritis and Cellulite Bone Broth Benefits for Digestion, Arthritis and Cellulite
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Coconut Oil - Healthy Gifts from the 'Tree of Life' Coconut Oil - Healthy Gifts from the 'Tree of Life'

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map